ELISpot and FluoroSpot Assay Market Size, Share & Trends Analysis Report By Product (Assay Kits, Analyzers, Ancillary products), By Application (Diagnostic Applications, Research Applications), By End-User, By Region, And By Segment Forecasts, 2023-2031

The ELISpot and FluoroSpot Assay Market Size is valued at USD 276.18 Mn in 2022 and is predicted to reach USD 512.39 Mn by the year 2031 at a 7.2 % CAGR during the forecast period for 2023-2031.

Several reasons are predicted to drive the ELISpot and FluoroSpot assay market. For starters, expanding vaccine research to combat drug-resistant strains, the increasing global prevalence of chronic illnesses, and technological advancements in ELISpot and FluoroSpot analyzers and test kits are likely to drive market expansion. ELISpot is an important technique in producing vaccines for various disorders, including AIDS, tuberculosis, malaria, cancer, and influenza. The ELISpot test is commonly used in clinical research to evaluate vaccinations. According to a June 2021 article published in BMC Infectious Diseases Journal, the FluoroSpot assay based on the ELISpot was more accurate than enzyme-linked immunoassay (ELISA) or flow cytometry (FCM). As a result, these assays are given priority to ensure precision in research diagnosis.

Key companies' strategic activities, such as product launches, approvals, alliances, and research projects, are also projected to drive market expansion. Ardigen and ImmuMap, for example, announced a research agreement in April 2021 aimed at discovering T-cell receptors (TCRs) receptive to tumor-associated neoantigens. The cooperation includes ELISpot tests, next-generation sequencing (NGS), MHC multimer labelling and sorting, and 10x Genomics Single Cell Immune Profiling. Such advancements are projected to stimulate assay innovation and, as a result, market growth. 

Competitive Landscape:

Some major key players in the ELISpot and FluoroSpot Assay Market:

• Oxford Immunotec (UK)
• Cellular Technology Limited (US)
• Mabtech (Sweden)
• Becton Dickinson and Company (US)
• Abcam plc. (UK) 
• Bio-Techne. (US)
• Mikrogen Diagnostik (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherlands)
• Medix Biochemica (Finland)
• Merck KGaA (Germany)
• Bio-Sys GmbH (Germany)
• Anogen-Yes Biotech Laboratories Ltd (Canada)
• Abnova Corporation (Taiwan)
• Biorbyt Ltd (UK),
• Tokyo Chemical Industry Co., Ltd. (Japan),
• MP BIOMEDICALS. (US),
• BOC Sciences. (US),
• ZenBio, Inc (US)
• Jackson ImmunoResearch Inc (US),
• Krishgen Biosystems. (India)
• NATIONAL ANALYTICAL CORPORATION (India),
• STEMCELL Technologies Inc. (Canada),
• SERVA Electrophoresis GmbH (Germany),
• IST Scitific LTD (England). 

Market Segmentation: 

The ELISpot and FluoroSpot Assay market is segmented based on product, application, and end-user. The market is segmented as assay kits by technique, by utility, by analyte, analyzers, and ancillary products based on product. The application segment includes diagnostic applications and research applications. Based on end-user, the market is bifurcated into hospitals & clinical labs, research institutes, and biopharmaceutical companies & CROs. 

Based On Product, The Assays & Kits Segment Is Accounted As A Major Contributor In The ELISpot And FluoroSpot Assay Market 

Assay kits are essential in a variety of applications, such as life science research, medicine development, and environmental monitoring. These applications include disease pathway research, screening for potential medication candidates, and evaluating biopharmaceutical manufacturing processes. Because of reasons such as the high prevalence of chronic diseases and the increased usage of these goods for vaccine development in clinical research, the assay kits segment maintains a dominant share. 

The Research Institutes Segment Witnessed Growth At A Rapid Rate 

The research institutes segment is expected to expand moderately over the projection period. The segment's expansion can be attributed to a greater emphasis on R&D activities in research institutes, particularly in the domains of immunology, infectious illnesses, and cancer research. More research institutes are expected to adopt ELISpot and Fluorospot assays for research and development purposes, propelling market growth in this sector. 

In The Region, The North American ELISpot and FluoroSpot Assay Market Holds A Significant Revenue Share 

Due to the presence of FDA-approved ELISpot and FluoroSpot test kits, the presence of health remuneration policies, the rise in chronic infection, and the rise in the older population, the United States dominates the global ELISpot and FluoroSpot assay in the North America region. The test kits segment is dominant in the United States because it is cost-effective and offers accurate therapy for patients in the United States. Germany, on the other hand, dominates the global ELISpot and FluoroSpot assay in the European area due to the presence of untapped prospects for ELISpot and FluoroSpot assay in Germany and the increased prevalence of cancer patients in Germany.  

ELISpot and FluoroSpot Assay Market Report Scope: